Unicycive Therapeutics, Inc.
Unicycive Theraputics (Nasdaq: UNCY) is a clinical-stage biotechnology company focused on developing kidney medications.
What is chronic kidney disease (CKD)?
“Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to properly filter waste and excess fluids from the blood. As kidney function declines, patients may develop complications including cardiovascular disease, anemia, bone disorders, and electrolyte imbalances.1-4”
在公司资料中查看What causes chronic kidney disease?
“CKD is commonly caused by diabetes and high blood pressure, although other medical conditions may also contribute to kidney damage over time. As CKD progresses, many patients eventually require dialysis to support kidney function.1-3”
在公司资料中查看What are the common complications of CKD?
“Common complications of CKD include elevated phosphorus levels (hyperphosphatemia), cardiovascular disease, bone disease, and vascular calcification. Hyperphosphatemia has been associated with increased morbidity and mortality in dialysis patients.1,5-8”
在公司资料中查看When do CKD patients typically require dialysis?
“Patients with advanced or end-stage chronic kidney disease (ESRD) may require dialysis when their kidneys can no longer adequately remove waste products and maintain fluid and electrolyte balance.2,3,9”
在公司资料中查看What is hyperphosphatemia?
“Hyperphosphatemia is a condition characterized by elevated phosphate levels in the blood. It occurs frequently in patients with chronic kidney disease on dialysis because damaged kidneys are unable to effectively remove excess phosphorus from the body. 6,10”
在公司资料中查看